Puma Vct IV Plc (PUMD) 0.0450 $PUMD
ProUroCare Medical to delist from OTCQB & file Form 15 with the SEC on or about 14 March 2014
M2 - Thu Mar 13, 5:31AM CDT
Prostate imaging company ProUroCare Medical (Other OTC
UMD) said on Wednesday that it plans to delist its common stock from trading on the OTCQB.
ProUroCare Medical Inc. to Delist from the OTCQB and Deregister Its Common Stock, Units and Warrants
Business Wire - Wed Mar 12, 3:00PM CDT
ProUroCare Medical Inc., a Nevada Corporation (OTCQB: PUMD), developer of the FDA-approved ProUroScan(TM) prostate imaging system, announced today that it intends to remove its common stock from trading on the OTCQB and to file a Form 15 with the Securities and Exchange Commission ("SEC"
on or about March 14, 2014. The Company also announced that because its common stock, warrants and units are held by less than 300 holders of record and were held by less than 300 holders of record as of January 1, 2014, it expects to terminate the registration of its common stock, warrants and units under Section 12(g) and to suspend its reporting obligations under Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act" by filing the Form 15 with the SEC.
ProUroCare Announces Changes to Management and Board of Directors
Business Wire - Mon Apr 29, 8:00AM CDT
ProUroCare Medical Inc. (OTCQB: PUMD) is pleased to announce the appointment of Stan Myrum as Interim CEO of the company and as a Director on its Board of Directors. Stan has over 30 years of medical device experience with Medtronic where he provided executive leadership in Operations, Supply Chain, Quality, Regulatory, Clinical and Product Development. In addition, he was Medtronic's Vice President of Operations and Technology for Europe, Middle East and Africa for six years. Since his retirement from Medtronic in 2007 Stan has provided consulting services to medical device start-up companies (including ProUroCare) as well as conducting due diligence for medium to large venture capital and medical device companies. Myrum stated, "I am very excited about this opportunity to lead the commercialization efforts for this exciting prostate imaging technology in a field of such significant unmet medical needs."
ProUroCare Medical to delist from OTCQB & file Form 15 with the SEC on or about 14 March 2014
M2 - Thu Mar 13, 5:31AM CDT
Prostate imaging company ProUroCare Medical (Other OTC
UMD) said on Wednesday that it plans to delist its common stock from trading on the OTCQB. ProUroCare Medical Inc. to Delist from the OTCQB and Deregister Its Common Stock, Units and Warrants
Business Wire - Wed Mar 12, 3:00PM CDT
ProUroCare Medical Inc., a Nevada Corporation (OTCQB: PUMD), developer of the FDA-approved ProUroScan(TM) prostate imaging system, announced today that it intends to remove its common stock from trading on the OTCQB and to file a Form 15 with the Securities and Exchange Commission ("SEC"
on or about March 14, 2014. The Company also announced that because its common stock, warrants and units are held by less than 300 holders of record and were held by less than 300 holders of record as of January 1, 2014, it expects to terminate the registration of its common stock, warrants and units under Section 12(g) and to suspend its reporting obligations under Section 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act" by filing the Form 15 with the SEC. ProUroCare Announces Changes to Management and Board of Directors
Business Wire - Mon Apr 29, 8:00AM CDT
ProUroCare Medical Inc. (OTCQB: PUMD) is pleased to announce the appointment of Stan Myrum as Interim CEO of the company and as a Director on its Board of Directors. Stan has over 30 years of medical device experience with Medtronic where he provided executive leadership in Operations, Supply Chain, Quality, Regulatory, Clinical and Product Development. In addition, he was Medtronic's Vice President of Operations and Technology for Europe, Middle East and Africa for six years. Since his retirement from Medtronic in 2007 Stan has provided consulting services to medical device start-up companies (including ProUroCare) as well as conducting due diligence for medium to large venture capital and medical device companies. Myrum stated, "I am very excited about this opportunity to lead the commercialization efforts for this exciting prostate imaging technology in a field of such significant unmet medical needs."
